organization · Reporting owner
SB INVESTMENT ADVISERS (UK) LTD
Disclosed activity across 15 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | 10% owner | September 16, 2019 | March 18, 2020 |
| Coupang, Inc.CPNG · Entity 3157 | 10% owner | August 20, 2025 | August 23, 2025 |
| DoorDash, Inc.DASH · Entity 1541 | 10% owner | October 27, 2021 | October 29, 2021 |
| Getaround, IncGETR · Entity 36866 | 10% owner | December 08, 2022 | December 19, 2022 |
| Opendoor Technologies Inc.OPEN · Entity 4242 | 10% owner | September 16, 2021 | September 20, 2021 |
| View, Inc.VIEW · Entity 91225 | 10% owner | March 08, 2021 | March 18, 2021 |
| WeWork Inc.WE · Entity 89201 | 10% owner | October 20, 2021 | November 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 16, 2019 · Filed March 18, 2020
Jointly reported with SOFTBANK VISION FUND (AIV M2) L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,836,232 |
Reported balance
After 2020-02-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-02-19 · Conversion · Acquired 3,836,232 · Balance 3,836,232 F1: The Class B Common Stock is convertible at any time at the option of the holder into Class A Common Stock on a 1:1 basis and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions), and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F3: Represents securities held directly by SoftBank Vision Fund (AIV M2) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for portfolio management and risk management. SBIA UK disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectSee footnote | 3,836,232 |
Reported balance
After 2019-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-09-16 · Conversion · Acquired 3,836,232 · Balance 3,836,232 F1: The Class B Common Stock is convertible at any time at the option of the holder into Class A Common Stock on a 1:1 basis and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions), and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F3: Represents securities held directly by SoftBank Vision Fund (AIV M2) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for portfolio management and risk management. SBIA UK disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-02-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-19 · Conversion · Disposed 3,836,232 · Balance 0 F1: The Class B Common Stock is convertible at any time at the option of the holder into Class A Common Stock on a 1:1 basis and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions), and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F3: Represents securities held directly by SoftBank Vision Fund (AIV M2) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for portfolio management and risk management. SBIA UK disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2019-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-09-16 · Conversion · Disposed 2,791,300 · Balance 0 F2: The Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock (the "Convertible Preferred Stock") automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock. There is no expiration date for the Convertible Preferred Stock. F1: The Class B Common Stock is convertible at any time at the option of the holder into Class A Common Stock on a 1:1 basis and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions), and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F3: Represents securities held directly by SoftBank Vision Fund (AIV M2) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for portfolio management and risk management. SBIA UK disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2019-09-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-09-16 · Conversion · Disposed 1,044,932 · Balance 0 F2: The Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock (the "Convertible Preferred Stock") automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock. There is no expiration date for the Convertible Preferred Stock. F1: The Class B Common Stock is convertible at any time at the option of the holder into Class A Common Stock on a 1:1 basis and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions), and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F3: Represents securities held directly by SoftBank Vision Fund (AIV M2) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for portfolio management and risk management. SBIA UK disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Common Stock is convertible at any time at the option of the holder into Class A Common Stock on a 1:1 basis and has no expiration date. Additionally, all outstanding shares of Class B Common Stock will convert automatically into Class A Common Stock upon any transfer, whether or not for value (subject to certain exceptions), and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.
F2: The Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock (the "Convertible Preferred Stock") automatically converted into Class B Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock. There is no expiration date for the Convertible Preferred Stock.
F3: Represents securities held directly by SoftBank Vision Fund (AIV M2) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for portfolio management and risk management. SBIA UK disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose.
Coupang, Inc.
Report date August 20, 2025 · Filed August 23, 2025
Jointly reported with SVF Investments (UK) Ltd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 289,542,259 |
Reported balance
After 2025-08-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-08-20 · Sale · Disposed 20,000,000 · Balance 289,542,259 F1: The securities reported herein are held of record by SVF Investments (UK) Limited ("SVF Investments"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") of SVF Investments, is exclusively responsible for managing SVF Investments in accordance with the Alternative Investment Fund Managers Directive, and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF Investments, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, and disposal of the investments held by SVF Investments. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein are held of record by SVF Investments (UK) Limited ("SVF Investments"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") of SVF Investments, is exclusively responsible for managing SVF Investments in accordance with the Alternative Investment Fund Managers Directive, and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF Investments, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, and disposal of the investments held by SVF Investments.
DoorDash, Inc.
Report date October 27, 2021 · Filed October 29, 2021
Jointly reported with SVF Fast (Cayman) Ltd, SOFTBANK VISION FUND (AIV M2) L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 33,573,485 |
Reported balance
After 2021-10-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-10-27 · Sale · Disposed 10,000,000 · Balance 33,573,485 F1: SVF Fast (Cayman) Limited ("SVF Fast") is the record holder of 3,573,485 shares of Common Stock and SVF Swift (Cayman) Limited ("SVF Swift") is the record holder of 30,000,000 shares of Common Stock. SVF Swift is a wholly owned subsidiary of SVF Fast, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P. ("AIV M2"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing AIV M2 in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of AIV M2, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of AIV M2's investments. |
Filing footnotes · ownership attribution and instrument terms
F1: SVF Fast (Cayman) Limited ("SVF Fast") is the record holder of 3,573,485 shares of Common Stock and SVF Swift (Cayman) Limited ("SVF Swift") is the record holder of 30,000,000 shares of Common Stock. SVF Swift is a wholly owned subsidiary of SVF Fast, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P. ("AIV M2"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing AIV M2 in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of AIV M2, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of AIV M2's investments.
Getaround, Inc
Report date December 08, 2022 · Filed December 19, 2022
Jointly reported with SVF Fetch (Cayman) Ltd, SoftBank Vision Fund L.P., SVF Sync Holdings (Cayman) Ltd, SVF Holdings (UK) LLP, SOFTBANK VISION FUND (AIV M2) L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 21,516,384 |
Reported balance
Holding disclosure · report date 2022-12-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 21,516,384 F1: Includes 12,885,948 shares of Common Stock held of record by SoftBank Vision Fund (AIV M2) L.P. and 8,630,436 shares of Common Stock held of record by SVF Fetch (Cayman) Limited. F2: Softbank Vision Fund L.P. is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Sync Holdings (Cayman) Limited, which is the sole owner of SVF Fetch (Cayman) Limited. SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") of each of Softbank Vision Fund L.P. and SoftBank Vision Fund (AIV M2) L.P. As AIFM, SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of Softbank Vision Fund L.P.'s and SoftBank Vision Fund (AIV M2) L.P.'s investments. As a result of these relationships, the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interests therein. |
| Earnout SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-12-08 | IndirectSee footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2022-12-08 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: Pursuant to the Merger Agreement, dated as of May 11, 2022, by and among InterPrivate II Acquisition Corp., TMPST Merger Sub I Inc., TMPST Merger Sub II LLC, and Getaround, Inc., SVF Fetch (Cayman) Limited and SoftBank Vision Fund (AIV M2) L.P. will be entitled to receive 4,041,743 shares and 6,034,653 shares of Common Stock, respectively, in each case issuable as earnout shares based on the daily volume weighted average price of the Issuer's Common Stock achieving various price targets ($13.50, $17.00, $25.00, $30.00, $37.00, $46.00 and $55.00) for a period of at least 20 days out of 30 consecutive trading days, as may be adjusted. F2: Softbank Vision Fund L.P. is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Sync Holdings (Cayman) Limited, which is the sole owner of SVF Fetch (Cayman) Limited. SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") of each of Softbank Vision Fund L.P. and SoftBank Vision Fund (AIV M2) L.P. As AIFM, SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of Softbank Vision Fund L.P.'s and SoftBank Vision Fund (AIV M2) L.P.'s investments. As a result of these relationships, the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 12,885,948 shares of Common Stock held of record by SoftBank Vision Fund (AIV M2) L.P. and 8,630,436 shares of Common Stock held of record by SVF Fetch (Cayman) Limited.
F2: Softbank Vision Fund L.P. is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Sync Holdings (Cayman) Limited, which is the sole owner of SVF Fetch (Cayman) Limited. SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") of each of Softbank Vision Fund L.P. and SoftBank Vision Fund (AIV M2) L.P. As AIFM, SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of Softbank Vision Fund L.P.'s and SoftBank Vision Fund (AIV M2) L.P.'s investments. As a result of these relationships, the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interests therein.
F3: Pursuant to the Merger Agreement, dated as of May 11, 2022, by and among InterPrivate II Acquisition Corp., TMPST Merger Sub I Inc., TMPST Merger Sub II LLC, and Getaround, Inc., SVF Fetch (Cayman) Limited and SoftBank Vision Fund (AIV M2) L.P. will be entitled to receive 4,041,743 shares and 6,034,653 shares of Common Stock, respectively, in each case issuable as earnout shares based on the daily volume weighted average price of the Issuer's Common Stock achieving various price targets ($13.50, $17.00, $25.00, $30.00, $37.00, $46.00 and $55.00) for a period of at least 20 days out of 30 consecutive trading days, as may be adjusted.
Opendoor Technologies Inc.
Report date September 16, 2021 · Filed September 20, 2021
Jointly reported with SVF Excalibur (Cayman) Ltd, SVF Endurance (Cayman) Ltd, SOFTBANK VISION FUND (AIV M1) L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 41,420,282 |
Reported balance
After 2021-09-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-09-16 · Sale · Disposed 32,200,000 · Balance 41,420,282 F1: The securities reported herein are held of record by SVF Excalibur (Cayman) Limited, which is a wholly owned subsidiary of SVF Endurance (Cayman) Limited, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. F2: As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s investments. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein are held of record by SVF Excalibur (Cayman) Limited, which is a wholly owned subsidiary of SVF Endurance (Cayman) Limited, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly.
F2: As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s investments. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose.
View, Inc.
Report date March 08, 2021 · Filed March 18, 2021
Jointly reported with SVF Excalibur (Cayman) Ltd, SVF Endurance (Cayman) Ltd, SOFTBANK VISION FUND (AIV M1) L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnotes | 66,194,110 |
Reported balance
Holding disclosure · report date 2021-03-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 66,194,110 F1: The securities reported herein are held of record by SVF Excalibur (Cayman) Limited, which is a wholly owned subsidiary of SVF Endurance (Cayman) Limited, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. F2: As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s investments. As a result, each of the reporting persons may be deemed to share beneficial ownership of the securities reported herein. Each of them disclaims any such beneficial ownership except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein are held of record by SVF Excalibur (Cayman) Limited, which is a wholly owned subsidiary of SVF Endurance (Cayman) Limited, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly.
F2: As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s investments. As a result, each of the reporting persons may be deemed to share beneficial ownership of the securities reported herein. Each of them disclaims any such beneficial ownership except to the extent of its pecuniary interest therein.
WeWork Inc.
Report date October 20, 2021 · Filed November 01, 2021
Jointly reported with SVF Endurance (Cayman) Ltd, SOFTBANK VISION FUND (AIV M1) L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 81,077,918 |
Reported balance
Holding disclosure · report date 2021-10-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 81,077,918 F1: Securities held of record by SVF Endurance (Cayman) Limited ("SVFE"). SVFE is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2031-10-20 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2021-10-20 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Securities held of record by SVF Endurance (Cayman) Limited ("SVFE"). SVFE is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities held of record by SVF Endurance (Cayman) Limited ("SVFE"). SVFE is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
Past disclosures · reporting ended (8)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Compass, Inc.
Report date March 24, 2025 · Filed March 26, 2025
Jointly reported with SVF Excalibur (Cayman) Ltd, SVF Endurance (Cayman) Ltd, SOFTBANK VISION FUND (AIV M1) L.P.
Section 16 reporting ended · disclosed 2025-03-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnotes | 48,070,273 |
Reported balance
After 2025-03-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-03-24 · Sale · Disposed 10,000,000 · Balance 48,070,273 F1: The securities reported herein are held of record by SVF Excalibur (Cayman) Limited, which is a wholly owned subsidiary of SVF Endurance (Cayman) Limited, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. F2: As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s investments. As a result, each of the reporting persons may be deemed to share beneficial ownership of the securities reported herein. Each of them disclaims any such beneficial ownership except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein are held of record by SVF Excalibur (Cayman) Limited, which is a wholly owned subsidiary of SVF Endurance (Cayman) Limited, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly.
F2: As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s investments. As a result, each of the reporting persons may be deemed to share beneficial ownership of the securities reported herein. Each of them disclaims any such beneficial ownership except to the extent of its pecuniary interest therein.
Energy Vault Holdings, Inc.
Report date January 15, 2026 · Filed January 20, 2026
Jointly reported with SOFTBANK VISION FUND (AIV M2) L.P.
Section 16 reporting ended · disclosed 2026-01-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 15,535,631 |
Reported balance
After 2026-01-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-01-15 · Sale · Disposed 3,000,000 · Balance 15,535,631 F1: Securities held of record by SoftBank Vision Fund (AIV M2) L.P. ("AIV M2"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing AIV M2 in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of AIV M2, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of AIV M2's investments |
Filing footnotes · ownership attribution and instrument terms
F1: Securities held of record by SoftBank Vision Fund (AIV M2) L.P. ("AIV M2"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing AIV M2 in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of AIV M2, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of AIV M2's investments
Guardant Health, Inc.
Report date October 09, 2020 · Filed October 13, 2020
Jointly reported with SVF Bluebird (Cayman) Ltd, SVF Enterprise (Cayman) Ltd, SVF Endurance (Cayman) Ltd, SOFTBANK VISION FUND (AIV M1) L.P.
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 7,037,960 |
Reported balance
After 2020-10-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-10-09 · Sale · Disposed 7,000,000 · Balance 7,037,960 F1: These securities are held of record by SVF Bluebird (Cayman) Limited, which is a subsidiary of SVF Enterprise (Cayman) Limited. SVF Enterprise (Cayman) Limited is a subsidiary of SVF Endurance (Cayman) Limited. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager, or AIFM, of SoftBank Vision Fund (AIV M1) L.P., and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. (continued to Fn. 2) F2: (Continued from Fn.1) As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s Investments. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held of record by SVF Bluebird (Cayman) Limited, which is a subsidiary of SVF Enterprise (Cayman) Limited. SVF Enterprise (Cayman) Limited is a subsidiary of SVF Endurance (Cayman) Limited. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager, or AIFM, of SoftBank Vision Fund (AIV M1) L.P., and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. (continued to Fn. 2)
F2: (Continued from Fn.1) As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s Investments. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose.
Relay Therapeutics, Inc.
Report date August 25, 2026 · Filed August 28, 2026
Jointly reported with SVF Pauling (Cayman) Ltd, SOFTBANK VISION FUND (AIV M2) L.P.
Section 16 reporting ended · disclosed 2026-08-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 21,904,963 |
Reported balance
After 2026-08-25 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-25 · Sale · Disposed 6,000,000 · Balance 21,904,963 F1: Securities held of record by SVF Pauling (Cayman) Limited, a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P. ("AIV M2"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing AIV M2 in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of AIV M2, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF Pauling (Cayman) Limited's investments. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities held of record by SVF Pauling (Cayman) Limited, a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P. ("AIV M2"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing AIV M2 in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of AIV M2, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF Pauling (Cayman) Limited's investments.
Roivant Sciences Ltd.
Report date September 28, 2023 · Filed October 03, 2023
Jointly reported with SVF Investments (UK) Ltd, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P.
Section 16 reporting ended · disclosed 2023-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee footnote | 73,031,667 |
Reported balance
After 2023-09-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-09-28 · Sale · Disposed 10,000,000 · Balance 73,031,667 F1: Securities held of record by SVF Investments (UK) Limited ("SVF Investments"). Softbank Vision Fund L.P. is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Investments. SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as the alternative investment fund manager ("AIFM") of SoftBank Vision Fund L.P. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund L.P.'s investments. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities held of record by SVF Investments (UK) Limited ("SVF Investments"). Softbank Vision Fund L.P. is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Investments. SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as the alternative investment fund manager ("AIFM") of SoftBank Vision Fund L.P. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund L.P.'s investments.
Uber Technologies, Inc
Report date January 07, 2021 · Filed January 11, 2021
Jointly reported with SB Cayman 2 Ltd., SoftBank Vision Fund (AIV S1) L.P.
Section 16 reporting ended · disclosed 2021-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 184,228,178 |
Reported balance
After 2021-01-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-01-07 · Sale · Disposed 38,000,000 · Balance 184,228,178 F1: SB Cayman 2 Limited is wholly owned by SoftBank Vision Fund (AIV S1) LP, a Delaware limited partnership ("Vision Fund"). SB Investment Advisers (UK) Limited, a wholly owned subsidiary of SoftBank Group Corp., has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing the Vision Fund in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of the Vision Fund, SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting, and disposal of the Vision Fund's Investments. SB Cayman 2 Limited has granted a proxy to a third party with respect to all voting interests in the Company in excess of 9.9% of its outstanding stock. F2: (Continued from footnote 2) This proxy will automatically terminate following approval of the Committee on Foreign Investment in the United States. Each such entity disclaims beneficial ownership of such shares except to the extent of such entity's pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes |
Filing footnotes · ownership attribution and instrument terms
F1: SB Cayman 2 Limited is wholly owned by SoftBank Vision Fund (AIV S1) LP, a Delaware limited partnership ("Vision Fund"). SB Investment Advisers (UK) Limited, a wholly owned subsidiary of SoftBank Group Corp., has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing the Vision Fund in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of the Vision Fund, SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting, and disposal of the Vision Fund's Investments. SB Cayman 2 Limited has granted a proxy to a third party with respect to all voting interests in the Company in excess of 9.9% of its outstanding stock.
F2: (Continued from footnote 2) This proxy will automatically terminate following approval of the Committee on Foreign Investment in the United States. Each such entity disclaims beneficial ownership of such shares except to the extent of such entity's pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes
Vir Biotechnology, Inc.
Report date December 01, 2025 · Filed December 03, 2025
Jointly reported with SVF Endurance (Cayman) Ltd, SOFTBANK VISION FUND (AIV M1) L.P.
Section 16 reporting ended · disclosed 2025-12-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 13,728,924 |
Reported balance
After 2025-12-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-01 · Sale · Disposed 191,854 · Balance 13,728,924 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2794 to $5.855. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2794 to $5.855. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
Zymergen Inc.
Report date October 19, 2022 · Filed October 21, 2022
Jointly reported with SVF Excalibur (Cayman) Ltd, SVF Endurance (Cayman) Ltd, SOFTBANK VISION FUND (AIV M1) L.P.
Section 16 reporting ended · disclosed 2022-10-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2022-10-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-10-19 · Other · Disposed 26,614,219 · Balance 0 F1: Pursuant to the Merger Agreement, dated July 24, 2022 (the "Merger Agreement"), by and among the Issuer, Ginkgo Bioworks Holdings, Inc. ("Ginkgo") and Pepper Merger Subsidiary Inc., the Issuer became an indirect wholly owned subsidiary of Ginkgo upon consummation of the merger on October 19, 2022 (the "Effective Time"), as provided for in the Merger Agreement. At the Effective Time, each share of the Issuer's common stock was automatically cancelled, extinguished and converted into the right to receive 0.9179 shares of Class A common stock of Ginkgo, with fractional shares paid in cash, without interest. F2: The securities reported herein are held of record by SVF Excalibur (Cayman) Limited, which is a wholly owned subsidiary of SVF Endurance (Cayman) Limited, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. F3: As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s investments. As a result, each of the reporting persons may be deemed to share beneficial ownership of the securities reported herein, but disclaims beneficial ownership except to the extent of the pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, dated July 24, 2022 (the "Merger Agreement"), by and among the Issuer, Ginkgo Bioworks Holdings, Inc. ("Ginkgo") and Pepper Merger Subsidiary Inc., the Issuer became an indirect wholly owned subsidiary of Ginkgo upon consummation of the merger on October 19, 2022 (the "Effective Time"), as provided for in the Merger Agreement. At the Effective Time, each share of the Issuer's common stock was automatically cancelled, extinguished and converted into the right to receive 0.9179 shares of Class A common stock of Ginkgo, with fractional shares paid in cash, without interest.
F2: The securities reported herein are held of record by SVF Excalibur (Cayman) Limited, which is a wholly owned subsidiary of SVF Endurance (Cayman) Limited, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SoftBank Vision Fund (AIV M1) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly.
F3: As AIFM of SoftBank Vision Fund (AIV M1) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M1) L.P.'s investments. As a result, each of the reporting persons may be deemed to share beneficial ownership of the securities reported herein, but disclaims beneficial ownership except to the extent of the pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2023 Filed Feb 1, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,316 | $28.88 | $95,752.15 |
DisclosureSEC source: 0000899243-23-003181 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,264,266 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.70 to $28.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 11,904 | $30.21 | $359,635.32 |
DisclosureSEC source: 0000899243-23-003181 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,267,582 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.7185. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 67,026 | $29.32 | $1,965,470.42 |
DisclosureSEC source: 0000899243-23-003181 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,279,486 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.02 to $29.9999. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 30,112 | $28.45 | $856,779.75 |
DisclosureSEC source: 0000899243-23-002713 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,346,512 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.83. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,400 | $27.80 | $177,927.68 |
DisclosureSEC source: 0000899243-23-002713 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,376,624 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 122,773 | $27.51 | $3,377,055.52 |
DisclosureSEC source: 0000899243-23-002444 · doc4.xml · nonDerivative · entry 4 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,383,024 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.62. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 21,585 | $26.86 | $579,745.04 |
DisclosureSEC source: 0000899243-23-002444 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,505,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.41 to $26.9955. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 65,802 | $26.59 | $1,749,866.01 |
DisclosureSEC source: 0000899243-23-002444 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,527,382 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.94. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,037 | $25.95 | $104,744.41 |
DisclosureSEC source: 0000899243-23-002444 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,593,184 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.87 to $25.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 102,467 | $26.31 | $2,696,408.86 |
DisclosureSEC source: 0000899243-23-002222 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,597,221 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.12 to $26.8476. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 88,372 | $26.24 | $2,318,748.72 |
DisclosureSEC source: 0000899243-23-002222 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,699,688 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.05 to $26.65. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 94,199 | $26.54 | $2,499,749.44 |
DisclosureSEC source: 0000899243-23-001914 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,788,060 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.16 to $26.92. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 105,623 | $26.70 | $2,819,827.79 |
DisclosureSEC source: 0000899243-23-001914 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,882,259 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.87. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 11,856 | $25.84 | $306,300.95 |
DisclosureSEC source: 0000899243-23-001914 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,987,882 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.53 to $25.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 78,165 | $26.24 | $2,051,276.28 |
DisclosureSEC source: 0000899243-23-001707 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,999,738 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.015 to $26.69. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 900 | $25.92 | $23,330.97 |
DisclosureSEC source: 0000899243-23-001707 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,077,903 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.85 to $25.97. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 70,575 | $26.41 | $1,863,885.75 |
DisclosureSEC source: 0000899243-23-001707 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,078,803 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.65. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,974 | $26.11 | $129,873.13 |
DisclosureSEC source: 0000899243-23-001530 · doc4.xml · nonDerivative · entry 4 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,149,378 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.38. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 29,827 | $25.81 | $769,700.65 |
DisclosureSEC source: 0000899243-23-001530 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,154,352 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $25.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 56,781 | $26.19 | $1,487,287.45 |
DisclosureSEC source: 0000899243-23-001530 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,184,179 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.56. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 9,398 | $25.76 | $242,111.28 |
DisclosureSEC source: 0000899243-23-001530 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,240,960 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.47 to $25.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,000 | $25.47 | $25,468.00 |
DisclosureSEC source: 0000899243-23-001123 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,250,358 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.46 to $25.48. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 8,177 | $25.58 | $209,144.76 |
DisclosureSEC source: 0000899243-23-001123 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,251,358 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.46 to $25.84. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 44,169 | $25.55 | $1,128,460.53 |
DisclosureSEC source: 0000899243-23-000445 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,259,535 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.46 to $25.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,850 | $25.59 | $175,303.83 |
DisclosureSEC source: 0000899243-22-039557 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,303,704 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.46 to $25.97. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 23, 2022 Filed Dec 27, 2022 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 321 | $26.07 | $8,369.66 |
DisclosureSEC source: 0000899243-22-039418 · doc4.xml · nonDerivative · entry 4 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,310,554 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.0069 to $26.1084. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 23, 2022 Filed Dec 27, 2022 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 79,760 | $25.76 | $2,054,745.22 |
DisclosureSEC source: 0000899243-22-039418 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,310,875 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.57 to $25.9967. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 72,343 | $26.13 | $1,890,496.21 |
DisclosureSEC source: 0000899243-22-039418 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,390,635 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.21. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 22,801 | $25.87 | $589,902.91 |
DisclosureSEC source: 0000899243-22-039418 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,462,978 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $25.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 95,803 | $26.19 | $2,509,023.09 |
DisclosureSEC source: 0000899243-22-039249 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,485,779 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.31. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 15,927 | $25.76 | $410,268.37 |
DisclosureSEC source: 0000899243-22-039249 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,581,582 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.57 to $25.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 104,026 | $25.53 | $2,656,293.51 |
DisclosureSEC source: 0000899243-22-039249 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,597,509 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.46 to $25.71. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 21:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 8,831 | $27.25 | $240,643.87 |
DisclosureSEC source: 0000899243-22-037824 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,701,535 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.59. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 02:30 UTC | Coupang, Inc. CPNG · Entity 3157 | SaleClass A Common Stock | 35,000,000 | $18.50 | $647,500,000.00 |
DisclosureSEC source: 0000899243-22-037969 · doc4.xml · nonDerivative · entry 1 SVF Investments (UK) Ltd · CIK 0001716729 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 426,156,413 F1 · ownership.nature: The securities reported herein are held of record by SVF Investments (UK) Limited ("SVF Investments"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") of SVF Investments, is exclusively responsible for managing SVF Investments in accordance with the Alternative Investment Fund Managers Directive, and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF Investments, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting, and disposal of the investments held by SVF Investments. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 88,462 | $27.47 | $2,430,413.83 |
DisclosureSEC source: 0000899243-22-037824 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,710,366 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.66. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 17:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,100 | $28.08 | $171,303.25 |
DisclosureSEC source: 0000899243-22-037480 · doc4.xml · nonDerivative · entry 4 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,798,828 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.1625. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 17:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 40,276 | $27.39 | $1,103,030.76 |
DisclosureSEC source: 0000899243-22-037480 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,804,928 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 17:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 63,662 | $28.17 | $1,793,587.72 |
DisclosureSEC source: 0000899243-22-037480 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,845,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.26. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 17:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 102,291 | $27.65 | $2,828,018.82 |
DisclosureSEC source: 0000899243-22-037480 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,908,866 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.9975. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 20:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 71,126 | $27.39 | $1,948,205.15 |
DisclosureSEC source: 0000899243-22-037247 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,011,157 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.94. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 20:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 885 | $28.02 | $24,800.89 |
DisclosureSEC source: 0000899243-22-037247 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,082,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.01 to $28.0527. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 20:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 37,104 | $27.45 | $1,018,378.65 |
DisclosureSEC source: 0000899243-22-037247 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,083,168 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.98. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 17:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 17,264 | $27.21 | $469,670.57 |
DisclosureSEC source: 0000899243-22-037092 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,120,272 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.27. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 17:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 39,729 | $27.30 | $1,084,744.72 |
DisclosureSEC source: 0000899243-22-037092 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,137,536 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.48. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 16:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 65,213 | $27.27 | $1,778,195.48 |
DisclosureSEC source: 0000899243-22-036931 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,177,265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.41. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 18:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 720 | $27.13 | $19,534.54 |
DisclosureSEC source: 0000899243-22-036796 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,242,478 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.15. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 18:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 25,259 | $27.21 | $687,282.23 |
DisclosureSEC source: 0000899243-22-036796 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,243,198 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27 to $27.85. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 16:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 73,030 | $27.18 | $1,984,699.80 |
DisclosureSEC source: 0000899243-22-036376 · doc4.xml · nonDerivative · entry 3 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,268,457 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.46. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 16:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,070 | $28.01 | $29,967.06 |
DisclosureSEC source: 0000899243-22-036376 · doc4.xml · nonDerivative · entry 2 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,341,487 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.03. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 16:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 135,931 | $27.54 | $3,742,941.64 |
DisclosureSEC source: 0000899243-22-036376 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,342,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $27.9976. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.